NCT04278690 Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
| NCT ID | NCT04278690 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Medication Administered in Error |
| Study Type | INTERVENTIONAL |
| Enrollment | 425 participants |
| Start Date | 2021-03-10 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 425 participants in total. It began in 2021-03-10 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized controlled study of parents of children to be discharged from the neonatal intensive care unit at Bellevue and Elmhurst hospitals. A total of 425 subjects will be recruited across two sites over preparatory phases and two primary study phases.
Eligibility Criteria
Inclusion Criteria: 1. English or Spanish-speaking 2. 18 years of age and older 3. Child discharged home with a Rx for \>1 daily liquid medication (other than multivitamin) 4. Primary person who will administers child's medications. 5. Willingness and ability to participate Exclusion Criteria: 1. Does not have a working phone number 2. Does not have access to internet (via computer/smartphone) 3. Does not have a mobile phone that receives texts. 4. Not able to return to the hospital for their child's follow-up visit 5. Visual acuity worse than 20/50 according to the Rosenbaum Pocket Screener 6. Uncorrectable hearing impairment
Contact & Investigator
Hsiang Sharon Yin
PRINCIPAL INVESTIGATOR
NYU Langone
Frequently Asked Questions
Who can join the NCT04278690 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Medication Administered in Error. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04278690 currently recruiting?
Yes, NCT04278690 is actively recruiting participants. Contact the research team at hsiang.yin@nyulangone.org for enrollment information.
Where is the NCT04278690 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04278690 clinical trial?
NCT04278690 is sponsored by NYU Langone Health. The principal investigator is Hsiang Sharon Yin at NYU Langone. The trial plans to enroll 425 participants.